💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, steadily growing business, fully valued.
Sun Pharmaceutical Industries is scored on the pharma / healthcare framework. It keeps a healthy 19.1% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.07×). Free cash flow is worth about 0.2% of its market value.
Over the last 3 years revenue compounded at 11%/yr and profit at 11%/yr. Book value has grown 12%/yr. Return on equity is a healthy 13.8%. In the latest quarter profit fell 31% versus the prior quarter.
At 39× earnings, the stock sits at the 62nd percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~19%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 40.62 | — | — |
| P/B | 5 | 4.1 | worse |
| EV/EBITDA | 22.94 | 19.33 | worse |
| ROE | 13.79 | — | — |
| ROCE | 18.65 | 14.41 | better |
| ROA | 9.61 | 1.64 | better |
| Quick Ratio | 2.31 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
| Laurus Labs | 94.7 | 20.8 | 22.1% |
Revenue has grown every year across all 4 financial years shown. 11% CAGR over 3 years — steady double-digit compounder.
Net profit has risen every year — the hallmark of a compounder.
Operating margin has expanded from 21% to 25% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 14% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 11% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (10% spread) — a predictable, non-seasonal revenue stream.
Profit fell 31% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (21% → 12%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 52.7% — majority control intact. Promoters reduced 1.8pp over 4 quarters — watch whether this is planned divestment or pledge invocations.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.